Drug Profile
Research programme: antibacterial antibodies - Sorrento Therapeutics
Alternative Names: Anti-AIP mAbs; Anti-API1 mAb; Anti-API2 mAbs; Anti-MRSA antibodies - Sorrento Therapeutics; STI 001 program - Sorrento; STI-C0205; STI-C020XLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics
- Developer Montana State University; Ohio State University; Sorrento Therapeutics
- Class Antibodies; Bispecific antibodies; Monoclonal antibodies; Vaccines
- Mechanism of Action Immunostimulants; Peptide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections; Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Methicillin-resistant Staphylococcus aureus infections in USA (Parenteral)
- 23 Feb 2023 Discontinued - Preclinical for Pseudomonal infections in USA (Parenteral)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA (Parenteral)